ArticleAntimicrobial agents and chemotherapy2000
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.
Article in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed.
- Trial
- International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2005Trial
- Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.Antimicrobial agents and chemotherapy · 2005Trial
- Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2003Trial
- The Emerging PathogenInfection and drug resistance · 2024Review
- Increased prevalence of fungemia in Medina, Saudi Arabia.Frontiers in epidemiology · 2023Article
- Human gut bifidobacteria inhibit the growth of the opportunistic fungal pathogen Candida albicans.FEMS microbiology ecology · 2022Article
- Serum bridging molecules drive candidal invasion of human but not mouse endothelial cells.PLoS pathogens · 2022Article
- Appropriate empirical antifungal therapy is associated with a reduced mortality rate in intensive care unit patients with invasive fungal infection: A real-world retrospective study based on the MIMIC-IV database.Frontiers in medicine · 2022Article
- Combination of Miconazole and Domiphen Bromide Is Fungicidal against Biofilms of ResistantAntimicrobial agents and chemotherapy · 2020Article
- Network analysis of hyphae forming proteins inHeliyon · 2019Article
- Fluconazole-Resistant Candida parapsilosis Bloodstream Isolates with Y132F Mutation in ERG11 Gene, South Korea.Emerging infectious diseases · 2018Article
- Characterization of beta-tubulin DNA sequences withinCurrent medical mycology · 2018Article
- Synergistic Effect of Quinic Acid Derived FromFrontiers in microbiology · 2018Article
- A Review of Diagnostic Methods for Invasive Fungal Diseases: Challenges and Perspectives.Infectious diseases and therapy · 2017Review
- Revisiting Species Distribution and Antifungal Susceptibility of Candida Bloodstream Isolates from Latin American Medical Centers.Journal of fungi (Basel, Switzerland) · 2017Review
- Candida glabrata Biofilms: How Far Have We Come?Journal of fungi (Basel, Switzerland) · 2017Review
- Caspofungin-Non-SusceptibleIranian journal of public health · 2017Article
- Antifungal Activity of Propolis Against Yeasts Isolated From Blood Culture: In Vitro Evaluation.Journal of clinical laboratory analysis · 2016Article
- Use of cost effective and rapid molecular tools for identification ofCurrent medical mycology · 2016Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An international program of surveillance of bloodstream infections (BSI) in the United States, Canada, and Latin America detected 306 episodes of candidemia in 34 medical centers (22 in the United States, 6 in Canada, and 6 in Latin America) in 1997 and 328 episodes in 34 medical centers (22 in the United States, 5 in Canada, and 7 in Latin America) in 1998. Of the 634 BSI, 54.3% were due to Candida albicans, 16.4% were due to C. glabrata, 14.9% were due to C. parapsilosis, 8.2% were due to C. tropicalis, 1.6% were due to C. krusei, and 4.6% were due to other Candida spp. The percentage of BSI due to C. albicans decreased very slightly in the United States between 1997 and 1998 (56.2 to 54.4%; P = 0.68) and increased in both Canada (52.6 to 70.1%; P = 0.05) and Latin America (40.5 to 44. 6%; P = 0.67). C. glabrata was the second most common species observed overall, and the percentage of BSI due to C. glabrata increased in all three geographic areas between 1997 and 1998. C. parapsilosis was the third most prevalent BSI isolate in both Canada and Latin America, accounting for 7.0 and 18.5% of BSI, respectively. Resistance to fluconazole (MIC, >/=64 microgram/ml) and itraconazole (MIC, >/=1.0 microgram/ml) was observed infrequently in both 1997 (2.3 and 8.5%, respectively) and 1998 (1.5 and 7.6%, respectively). Among the different species of Candida, resistance to fluconazole and itraconazole was observed in C. glabrata and C. krusei, whereas isolates of C. albicans, C. parapsilosis, and C. tropicalis were all highly susceptible to both fluconazole (98.9 to 100% susceptible) and itraconazole (96.4 to 100% susceptible). Isolates from Canada and Latin America were generally more susceptible to both triazoles than U.S. isolates were. Continued surveillance appears necessary to detect these important changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.